Literature DB >> 4025228

Nevus cells within lymph nodes. Possible metastases from a benign intradermal nevus.

C Subramony, J R Lewin.   

Abstract

Two axillary lymph nodes from a patient who underwent modified radical mastectomy for carcinoma of the breast showed benign nevus cells in the fibrous capsule and within afferent lymphatics. Subsequently, an intradermal nevus from the area of drainage of the axillary lymph nodes was excised, which showed groups of nevus cells lying within small lymphatic channels. It is postulated that the nevus cells in the lymph node capsule could represent benign metastases from the intradermal nevus.

Entities:  

Mesh:

Year:  1985        PMID: 4025228     DOI: 10.1093/ajcp/84.2.220

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  4 in total

1.  The melanocyte differentiation program predisposes to metastasis after neoplastic transformation.

Authors:  Piyush B Gupta; Charlotte Kuperwasser; Jean-Philippe Brunet; Sridhar Ramaswamy; Wen-Lin Kuo; Joe W Gray; Stephen P Naber; Robert A Weinberg
Journal:  Nat Genet       Date:  2005-09-04       Impact factor: 38.330

2.  Immunostaining for the tumour suppressor gene p16 product is a useful marker to differentiate melanoma metastasis from lymph-node nevus.

Authors:  Daniela Mihic-Probst; Parvin Saremaslani; Paul Komminoth; Philipp U Heitz
Journal:  Virchows Arch       Date:  2003-10-24       Impact factor: 4.064

3.  Intradermal melanocytic nevus with lymphatic nevus cell embolus: A case report.

Authors:  Hyun-Soo Kim; Sang Hwa Lee; Hyung-Sik Moon; Youn Wha Kim
Journal:  Oncol Lett       Date:  2013-11-25       Impact factor: 2.967

4.  Melanocytic nevi in sentinel lymph nodes: association with cutaneous nevi and clinical relevance in patients with cutaneous melanomas.

Authors:  Lutz Kretschmer; Viktor Schnabel; Christian Kromer; Christoph Bauer-Büntzel; Annika Richter; Felix Bremmer; Fabian Kück; Katharina Julius; Christina Mitteldorf; Michael P Schön
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-20       Impact factor: 4.322

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.